NEW YORK, July 17, 2017 /PRNewswire/ --
If you want a Stock Review on NVCR, CVRS, NSPR or NXTM then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. Four stocks have been lined up by DailyStockTracker.com for review this morning: NovoCure Ltd (NASDAQ: NVCR), Corindus Vascular Robotics Inc. (NYSE MKT: CVRS),
Last Friday, Saint Helier, the Channel Islands-based NovoCure Ltd's stock dropped 3.28%, to close the day at $19.15. A total volume of 869,558 shares was traded, which was above their three months average volume of 816,880 shares. The Company's shares have surged 28.09% in the last month, 83.25% in the previous three months, and 143.95% on an YTD basis. The stock is trading 30.86% above its 50-day moving average and 96.17% above its 200-day moving average. Additionally, shares of NovoCure, which engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors, have a Relative Strength Index (RSI) of 69.13.
On July 12th, 2017, NovoCure announced that physicians at more than 600 cancer treatment centers in the US have been certified to prescribe Optune to newly diagnosed and recurrent glioblastoma (GBM) patients. Optune is the Company's wearable, portable, FDA-approved Tumor Treating Fields delivery system for the treatment of GBM. Physicians at an additional 350 medical institutions throughout the world also can prescribe Optune to GBM patients. The free research report on NVCR is available at:
Corindus Vascular Robotics
Shares in Waltham, Massachusetts headquartered Corindus Vascular Robotics Inc. rose 0.54%, finishing Friday's session at $1.85. The stock recorded a trading volume of 186,529 shares. The Company's shares have gained 20.13% in the last month, 55.46% over the previous three months, and 164.89% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 26.96% and 79.05%, respectively. Furthermore, shares of Corindus Vascular Robotics, which designs, manufactures, and sells robotic-assisted precision vascular intervention systems for use in interventional vascular procedures, have an RSI of 61.85. The complimentary report on CVRS can be downloaded at:
Tel Aviv, Israel headquartered InspireMD Inc.'s stock finished 2.97% higher at $0.45 last Friday at the close. A total volume of 215,095 shares was traded. The Company's shares are trading below their 50-day moving average by 18.36%. Additionally, shares of InspireMD, which focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex coronary and vascular diseases, have an RSI of 38.31. Visit us today and download our complete research report on NSPR for free at:
Lawrence, Massachusetts headquartered Nxstage Medical Inc.'s shares ended the session 0.08% higher at $24.28. The stock recorded a trading volume of 425,917 shares. Shares of the Company have advanced 3.32% in the last month. The stock is trading 3.27% above its 50-day moving average. Moreover, shares of Nxstage Medical, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have an RSI of 53.13.
On July 10th, 2017, Nxstage Medical announced plans to release its financial results for Q2 ended June 30th, 2017, on August 09th, 2017, before the opening of the financial markets. The Company will also host a conference call at 9:00 a.m. ET on the same day to discuss its Q2 financial results. The call will be webcast live and can be accessed under the investor relations section of the Company's website. Get free access to your technical report on NXTM at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All